

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Treatment Programs Under Consideration



The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found on the Cancer Drug Manual Drug Index website.

ULYNIV & ULYNIV4

Treatment	Indication: Under Review	Adverse Events
Programs	(Refer to protocol for more details)	
Nivolumab	Treatment of relapsed or refractory	Possible adverse events (any grade):
	Hodgkin Lymphoma	 Immune-mediated adverse reactions: (see <u>SCIMMUNE Resources</u>)
		o Skin:
		■ Rash
		Pruritus
		o Enterocolitis:
		■ Diarrhea
		Abdominal pain
		o Endocrine:
		Hypothyroidism/hyperthyroidism
		■ Fatigue
		o Pulmonary:
		Pneumonitis
		o Hepatic:
		Elevated alanine aminotransferase (ALT)
		o Renal
		Increased serum creatinine
		Infusion-related reactions

Dosing and Administration Information

Pre-medications:

- Antiemetic: low emetogenicity
- Infusion reaction: If prior reactions to nivolumab: diphenhydramine 50 mg PO, acetaminophen 325 to 975 mg PO, and hydrocortisone 25 mg IV

Dosing and Schedule:

- IV nivolumab 3 mg/kg (maximum dose 240 mg) every 2 weeks until disease progression or unacceptable toxicity
 - o To be given over 30 minutes using a 0.2 or 0.22 micron in-line filter

OR

- IV nivolumab 6 mg/kg (maximum dose 480 mg) every 4 weeks until disease progression or unacceptable toxicity
 - o To be given over 30 minutes using a 0.2 or 0.22 micron in-line filter

Additional Protocol Information:

Optional weekly nursing assessment

ULYVENETOR

Treatment	Indication: Under Review	Adverse Events
Programs	(Refer to protocol for more details)	
<u>Venetoclax</u>	Treatment of patients with relapsed or	Possible adverse events (any grade):
plus	refractory chronic lymphocytic leukemia	 Infusion-related reactions
Rituximab	(CLL) or small lymphocytic lymphoma	Neutropenia
	(SLL).	Diarrhea
		Nausea
		Anemia
		Upper respiratory tract infection
		Thrombocytopenia
		Fatigue
		Possible adverse events (≥ grade 3):
		Pneumonia
		Febrile neutropenia
		Autoimmune hemolytic anemia
		Tumour lysis syndrome (TLS)

Dosing and Administration Information

Pre-medications:

- Antiemetic: low emetogenicity
- For IV rituximab:


diphenhydramine 50 mg PO and acetaminophen 650- 975 mg PO prior to rituximab and then q 4 h during the infusion, if the infusion exceeds 4 hours

• For SC rituximab:

diphenhydramine 50 mg PO and acetaminophen 650- 975 mg PO prior to rituximab

Dosing and Schedule:

Ramp-up Phase				
	20mg daily	Week 1		
	50mg daily	Week 2		
Oral Venetoclax*	100 mg daily	Week 3		
	200 mg daily	Week 4		
	400 mg daily	Week 5		



Maintenance Therapy			
Oral Venetoclax	400 mg daily	For two years or until	
oral remotestan		disease progression	

* Venetoclax must be taken with food approximately at the same time each day. Venetoclax should not be chewed, crushed, or broken prior to swallowing.

Grapefruit and grapefruit juice must be avoided for the duration of treatment.

The following resources are available for Venetoclax:

- Patient Handout
- Education Bulletin
- Nursing Information
- Pharmacy Information

^{**}Every 28 days for 6 cycles.

ULUAVOSIF

Treatment	Indication: Under Review	Adverse Events
Programs	(Refer to protocol for more details)	
Osimertinib	Treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC)	Possible adverse events (any grade): Rash or acne Dry skin Pruritus Diarrhea Paronychia Cardiomyopathy QT prolongation Stomatitis Decreased appetite Interstitial lung disease Elevated alanine aminotransferase (ALT)

Dosing and Administration Information

Pre-medications:

• No pre-medications required

Dosing and Schedule:

• Oral osimertinib 80 mg once daily until disease progression.

Additional Protocol Information:

• Grapefruit and grapefruit juice must be avoided for the duration of treatment.

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL	
To subscribe or update contact information, please contact:		
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca	